Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W J Loos

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivoA Sparreboom, J Verweij, M E van der Burg, et al.
Clinical Pharmacology and Therapeutics|April 22, 2011
Environmental and genetic factors affecting transport of imatinib by OATP1A2K Eechoute, R M Franke, W J Loos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatinA J Gelderblom, W J Loos, M J de Jonge, et al.
Journal of the National Cancer Institute|June 15, 1994
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09J H Schellens, A S Planting, B A van Acker, et al.
Anti-Cancer Drugs|August 7, 2001
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9J H Schellens, P Dombernowsky, J Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Anti-Cancer Drugs|November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinA Sparreboom, A S Planting, R C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 26, 1998
Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivoA Sparreboom, J Verweij, M E van der Burg, et al.
Clinical Pharmacology and Therapeutics|April 22, 2011
Environmental and genetic factors affecting transport of imatinib by OATP1A2K Eechoute, R M Franke, W J Loos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 4, 2000
Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatinA J Gelderblom, W J Loos, M J de Jonge, et al.
Journal of the National Cancer Institute|June 15, 1994
Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug E09J H Schellens, A S Planting, B A van Acker, et al.
Anti-Cancer Drugs|August 7, 2001
Population pharmacokinetics and dynamics in phase II studies of the novel bioreductive alkylating cytotoxic indoloquinone EO9J H Schellens, P Dombernowsky, J Cassidy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1997
Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumorsG J Creemers, C J Gerrits, J R Eckardt, et al.
European Journal of Cancer (Oxford, England : 1990)|December 16, 1998
Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumoursC J Gerrits, H Burris, J H Schellens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2000
Phase I pharmacologic study of oral topotecan and intravenous cisplatin: sequence-dependent hematologic side effectsM J de Jonge, W J Loos, H Gelderblom, et al.
Anti-Cancer Drugs|November 26, 1999
Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoproteinA Sparreboom, A S Planting, R C Jewell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 1999
A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)C J Gerrits, J H Schellens, H Burris, et al.
Pageof 7